C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home Markets Loading…
CYTH Equity

CYTH

OTCMKTS · CYTH

$9900.00
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 3/5
35/100 composite
Fundamentals24
Regulatory49
Market40
Editorial30
Composite · trailing 12 months

Cyngn's rating stands at Neutral, reinforced by a composite of 35.1 amidst a landscape of mixed pillar contributions. With the strongest support from the regulatory pillar, this component underscores the company's standing in a highly scrutinized jurisdiction with a relatively favorable posture. However, the overall conviction remains moderate at 3 out of 5, largely due to the constrained fundamentals driven by both disappointing revenue trends and a lack of operational efficiency. Market dynamics and editorial visibility offer lower comparative contributions, further solidifying the Neutral rating band.

The underlying weaknesses in Cyngn's financial data are pronounced. Year-over-year revenue growth has been negative, a stark contrast overshadowed by an otherwise strong gross margin exceeding industry norms. Yet, this is offset by significant negative operating margins, eroding potential profitability. The company’s financial condition is notably stretched, marked by a precarious cash burn ratio that indicates a delicate runway. The absence of net income further compounds concerns around financial sustainability, signaling a critical need for revenue stabilization or alternative financial strategies.

Going forward, stakeholders should focus on regulatory developments, as they hold the most promise for improved market positioning. With no recent enforcement hits, maintaining compliance status and navigating the complex regulatory landscape will be key to mitigating risk and possibly enhancing pillar strengths. Although financial conditions remain pressured, staying attuned to regulatory changes might unlock valuable strategic opportunities for the company.

Scored: 2026-08-25Valid through: 2026-10-09Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
IR & AgencyInvestor relations
Corporate DetailsCompany profile
Headquarters
1180 Alachua, FL 32616-1180
CEO
Howard S. Jonas
CFO
David Polinsky
SEC CIK
0000922247
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$23.6M
Enterprise value
$34.9M
Price to book
59.10
Price to sales
27.09
EV / EBITDA
-0.47
Revenue (TTM)
$871K
Gross profit (TTM)
$794K
EBITDA
$-24.7M
Operating margin
-3545.9%
Profit margin
0.0%
Rev growth YoY
-52.8%
Return on equity
-22663.9%
Return on assets
-284.3%
EPS (TTM)
$-0.90
Wall St. target price
$0.95
Shares outstanding
32.7M
Insider ownership
48.5%
Institutional ownership
11.4%
Beta
-0.57
Full-time employees
8
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for CYTH (CYTH)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for CYTH (CYTH), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Neutral / Wait. Mixed data profile. Await clearer directional signal. (0 bullish signals, 0 bearish signals.)

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for CYTH are maintained by Cannabis Investor News and refreshed throughout the trading day.